These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

426 related items for PubMed ID: 16054272

  • 1. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals.
    Gradoni L, Foglia Manzillo V, Pagano A, Piantedosi D, De Luna R, Gramiccia M, Scalone A, Di Muccio T, Oliva G.
    Vaccine; 2005 Nov 01; 23(45):5245-51. PubMed ID: 16054272
    [Abstract] [Full Text] [Related]

  • 2. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL, Holzmuller P, Gonçalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G.
    Vaccine; 2007 May 22; 25(21):4223-34. PubMed ID: 17395339
    [Abstract] [Full Text] [Related]

  • 3. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes.
    Lemesre JL, Holzmuller P, Cavaleyra M, Gonçalves RB, Hottin G, Papierok G.
    Vaccine; 2005 Apr 22; 23(22):2825-40. PubMed ID: 15780731
    [Abstract] [Full Text] [Related]

  • 4. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.
    Rafati S, Nakhaee A, Taheri T, Taslimi Y, Darabi H, Eravani D, Sanos S, Kaye P, Taghikhani M, Jamshidi S, Rad MA.
    Vaccine; 2005 May 25; 23(28):3716-25. PubMed ID: 15882533
    [Abstract] [Full Text] [Related]

  • 5. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge.
    Rodríguez-Cortés A, Ojeda A, López-Fuertes L, Timón M, Altet L, Solano-Gallego L, Sánchez-Robert E, Francino O, Alberola J.
    Vaccine; 2007 Nov 14; 25(46):7962-71. PubMed ID: 17942199
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.
    Fujiwara RT, Vale AM, França da Silva JC, da Costa RT, Quetz Jda S, Martins Filho OA, Reis AB, Corrêa Oliveira R, Machado-Coelho GL, Bueno LL, Bethony JM, Frank G, Nascimento E, Genaro O, Mayrink W, Reed S, Campos-Neto A.
    Vet Res; 2005 Nov 14; 36(5-6):827-38. PubMed ID: 16120256
    [Abstract] [Full Text] [Related]

  • 7. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
    Ramos I, Alonso A, Marcen JM, Peris A, Castillo JA, Colmenares M, Larraga V.
    Vaccine; 2008 Jan 17; 26(3):333-44. PubMed ID: 18093705
    [Abstract] [Full Text] [Related]

  • 8. Serological evaluation of experimentally infected dogs by LicTXNPx-ELISA and amastigote-flow cytometry.
    Silvestre R, Santarém N, Cunha J, Cardoso L, Nieto J, Carrillo E, Moreno J, Cordeiro-da-Silva A.
    Vet Parasitol; 2008 Nov 25; 158(1-2):23-30. PubMed ID: 18848397
    [Abstract] [Full Text] [Related]

  • 9. Detailed analysis of an experimental challenge model for Leishmania infantum (JPC strain) in dogs.
    Poot J, Rogers ME, Bates PA, Vermeulen A.
    Vet Parasitol; 2005 Jun 10; 130(1-2):41-53. PubMed ID: 15893068
    [Abstract] [Full Text] [Related]

  • 10. Gentamicin-attenuated Leishmania infantum: a clinicopathological study in dogs.
    Daneshvar H, Molaei MM, Afshar RM, Kamiabi H, Burchmore R, Hagan P, Phillips RS.
    Vet Immunol Immunopathol; 2009 May 15; 129(1-2):28-35. PubMed ID: 19147233
    [Abstract] [Full Text] [Related]

  • 11. The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine.
    Saraiva EM, de Figueiredo Barbosa A, Santos FN, Borja-Cabrera GP, Nico D, Souza LO, de Oliveira Mendes-Aguiar C, de Souza EP, Fampa P, Parra LE, Menz I, Dias JG, de Oliveira SM, Palatnik-de-Sousa CB.
    Vaccine; 2006 Mar 20; 24(13):2423-31. PubMed ID: 16386824
    [Abstract] [Full Text] [Related]

  • 12. Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs.
    Nogueira FS, Moreira MA, Borja-Cabrera GP, Santos FN, Menz I, Parra LE, Xu Z, Chu HJ, Palatnik-de-Sousa CB, Luvizotto MC.
    Vaccine; 2005 Sep 23; 23(40):4805-10. PubMed ID: 16011864
    [Abstract] [Full Text] [Related]

  • 13. Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection.
    Ramos I, Alonso A, Peris A, Marcen JM, Abengozar MA, Alcolea PJ, Castillo JA, Larraga V.
    Vaccine; 2009 Nov 12; 27(48):6695-703. PubMed ID: 19747996
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs.
    Saldarriaga OA, Travi BL, Park W, Perez LE, Melby PC.
    Vaccine; 2006 Mar 10; 24(11):1928-40. PubMed ID: 16310897
    [Abstract] [Full Text] [Related]

  • 15. The chimerical multi-component Q protein from Leishmania in the absence of adjuvant protects dogs against an experimental Leishmania infantum infection.
    Carcelén J, Iniesta V, Fernández-Cotrina J, Serrano F, Parejo JC, Corraliza I, Gallardo-Soler A, Marañón F, Soto M, Alonso C, Gómez-Nieto C.
    Vaccine; 2009 Oct 09; 27(43):5964-73. PubMed ID: 19666153
    [Abstract] [Full Text] [Related]

  • 16. Vaccination of dogs with six different candidate leishmaniasis vaccines composed of a chimerical recombinant protein containing ribosomal and histone protein epitopes in combination with different adjuvants.
    Poot J, Janssen LH, van Kasteren-Westerneng TJ, van der Heijden-Liefkens KH, Schijns VE, Heckeroth A.
    Vaccine; 2009 Jul 16; 27(33):4439-46. PubMed ID: 19500553
    [Abstract] [Full Text] [Related]

  • 17. Selection of appropriate serological tests to measure the incidence of natural Leishmania infantum infection during DNA/MVA prime/boost canine vaccine trials.
    Carson C, Antoniou M, Christodoulou V, Messaritakis I, Quinnell RJ, Blackwell JM, Courtenay O.
    Vet Parasitol; 2009 Jun 10; 162(3-4):207-13. PubMed ID: 19386420
    [Abstract] [Full Text] [Related]

  • 18. Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice.
    Rafati S, Zahedifard F, Azari MK, Taslimi Y, Taheri T.
    Exp Parasitol; 2008 Mar 10; 118(3):393-401. PubMed ID: 18093586
    [Abstract] [Full Text] [Related]

  • 19. Canine Leishmania vaccines: still a long way to go.
    Gradoni L.
    Vet Parasitol; 2015 Feb 28; 208(1-2):94-100. PubMed ID: 25620293
    [Abstract] [Full Text] [Related]

  • 20. Antigenicity of a whole parasite vaccine as promising candidate against canine leishmaniasis.
    Giunchetti RC, Reis AB, da Silveira-Lemos D, Martins-Filho OA, Corrêa-Oliveira R, Bethony J, Vale AM, da Silva Quetz J, Bueno LL, França-Silva JC, Nascimento E, Mayrink W, Fujiwara RT.
    Res Vet Sci; 2008 Aug 28; 85(1):106-12. PubMed ID: 17950391
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.